Bordetella Bronchiseptica + Avirulent Live Culture

Verify with FDA CVM →

18 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
1
Deaths Reported
560.0%
Death Rate

Active Ingredients

Bordetella Bronchiseptica + Avirulent Live Culture

Administration Routes

OralUnknownNasalSubcutaneousParenteral

Species Affected

Dog 18

Most Affected Breeds

Boxer (German Boxer) 4
Retriever - Labrador 3
Crossbred Canine/dog 2
Spitz - German Pomeranian 2
Maltese 2
Schnauzer (unspecified) 1
Shih Tzu 1
Shepherd Dog (unspecified) 1
Beagle 1
Chihuahua 1

Most Reported Reactions

Vomiting 10
Lethargy (see also Central nervous system depression in 'Neurological') 3
Other abnormal test result NOS 3
Not eating 2
Not drinking 2
Diarrhoea 2
Leucocytosis NOS 2
Generalised inflammation of eye 2
Facial swelling (see also 'Skin') 2
Lethargy (see also Central nervous system depression in Neurological) 2
Weight loss 1
Periodontal disorder 1

Outcome Breakdown

Recovered/Normal
11 (61.1%)
Ongoing
3 (16.7%)
Outcome Unknown
3 (16.7%)
Euthanized
1 (5.6%)

Data Summary

Metric Value
Total adverse event reports 18
Reports involving death 1
Case-fatality rate (reported events) 560.0%
Distinct species in reports 1
Distinct breeds in reports 10
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Bordetella Bronchiseptica + Avirulent Live Culture Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 18 adverse event reports referencing Bordetella Bronchiseptica + Avirulent Live Culture, including 1 reports in which the animal died — a 560.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Bordetella Bronchiseptica + Avirulent Live Culture. Reported administration routes include Oral, Unknown, Nasal, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Bordetella Bronchiseptica + Avirulent Live Culture reports are Dog (18 reports), with Dog accounting for the largest share. Within those species, Boxer (German Boxer) (4), Retriever - Labrador (3), Crossbred Canine/dog (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Bordetella Bronchiseptica + Avirulent Live Culture are Vomiting (10), Lethargy (see also Central nervous system depression in 'Neurological') (3), Other abnormal test result NOS (3), Not eating (2). Of the 18 reports with a coded outcome, Recovered/Normal is the leading category at 61.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bordetella Bronchiseptica + Avirulent Live Culture.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial